Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03540836 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT03540836 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT03540836, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study conducted at a single study center to characterize the relative bioavailability of relacorilant administered as 3×100-mg softgel capsules (Treatment A), 3×100 mg hard-shell capsules (Treatment B), and 6×50-mg hard shell capsules (Treatment C/reference) in healthy, fasted, adult subjects. Eligible subjects will participate in 3 treatment periods. During each treatment period, subjects will receive a single 300-mg relacorilant dose. An equal number of subjects will be randomized to each of 6 sequences.
Interventions
- DRUG Relacorilant (3x100 mg softgel capsules)
- DRUG Relacorilant (3x100 mg hard-shell capsules)
- DRUG Relacorilant (6x50mg hard-shell capsules)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-05-24 |
| Est. Completion | 2018-07-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03540836
The ClinicalTrials.gov registry entry for NCT03540836 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Relacorilant (3x100 mg softgel capsules) is the first listed.
NCT03540836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03540836 about?
NCT03540836 is a clinical study titled "A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants". This is an open-label, randomized, 3 treatment, 3-period, 6-sequence, crossover study conducted at a single study center to characterize the relative bioavailability of relacorilant administered as 3×100-mg softgel capsules (Treatment A), 3×100 mg hard-shell capsules (Treatment B), and 6×50-mg hard ...
What is the current status of trial NCT03540836?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2018-05-24. Estimated completion is 2018-07-25.
What interventions are being tested in trial NCT03540836?
The interventions under investigation include: Relacorilant (3x100 mg softgel capsules) (DRUG), Relacorilant (3x100 mg hard-shell capsules) (DRUG), Relacorilant (6x50mg hard-shell capsules) (DRUG).
Who is sponsoring clinical trial NCT03540836?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.